Compare CVS Health Corp (CVS) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Wipro Limited — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: CVS Health Corp is far larger — about 6.9× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (5.19%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Wipro Limited for 41 Days on average.
| CVS | WIT | |
|---|---|---|
Market Cap | $112.49B | $16.36B |
Volume | 8,467,392 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $110.60 | $3.06 |
52-Week Low | $70.08 | $1.61 |
Typical Hold Time | 83 Days | 41 Days |
Enterprise Value | $174.83B | $14.47B |
Dividend Yield | 3.02% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent gap-up momentum. The company maintains solid fundamentals with $890.88B revenue and 13.92% net margin in 2025, though recent quarters show earnings misses. Analyst sentiment is mixed with only 19% buy ratings, while AI partnerships and productivity gains provide growth catalysts.
Wipro presents a cautious opportunity with reasonable valuation (P/E 12.78) but faces execution risks amid competitive IT services market. The stock's outlook depends on reversing recent earnings misses while leveraging AI initiatives that have already boosted productivity equivalent to 20,000 workers according to company reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
